Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACP-501

- PMLiVE

AZ pays $273m for Ardelyx renal disease drug

Phase II candidate could tackle fluid overload in kidney and heart disorders

- PMLiVE

AZ share buyback suspension prompts M&A speculation

Analysts query new CEO Pascal Soriot’s intention to preserve cash reserves

- PMLiVE

AZ launches science blog LabTalk

Hopes new blog will build relationships with potential collaborators

- PMLiVE

AstraZeneca forges CRO alliance to bring biologic to China

MedImmune Subsidiary forms joint venture with WuXi

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

- PMLiVE

COPD needs to learn risk reductions lessons from heart disease

Takeda-backed report says HCPs working in COPD need to learn from progress made by their colleagues in cardiovascular medicine

AstraZeneca and BGT shelve experimental sepsis drug

Decision follows CytoFab’s poor mid-stage clinical trial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links